{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:47:09Z","timestamp":1791463629864,"version":"4.3.4"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010452","name":"Sociedad Argentina de Hipertensi\u00f3n Arterial","doi-asserted-by":"publisher","award":["ACY-1215"],"award-info":[{"award-number":["ACY-1215"]}],"id":[{"id":"10.13039\/501100010452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","award":["4021652"],"award-info":[{"award-number":["4021652"]}],"id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118112","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T12:45:47Z","timestamp":1757335547000},"page":"118112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Verubulin and its derivatives: Progress and promise in tubulin-targeted cancer therapy"],"prefix":"10.1016","volume":"300","author":[{"given":"Alireza","family":"Mousavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahfam","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loghman","family":"Firoozpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2416-5611","authenticated-orcid":false,"given":"Alireza","family":"Foroumadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejmech.2025.118112_bib1","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1002\/jcp.27978","article-title":"Microtubules: from understanding their dynamics to using them as potential therapeutic targets","volume":"234","author":"Ilan","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejmech.2025.118112_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12033-009-9193-5","article-title":"On and around microtubules: an overview","volume":"43","author":"Wade","year":"2009","journal-title":"Mol. Biotechnol."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118112_bib3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41580-018-0009-y","article-title":"Microtubule dynamics: an interplay of biochemistry and mechanics","volume":"19","author":"Brouhard","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118112_bib4","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2174\/1389450124666230731094837","article-title":"Microtubules and cell division: potential pharmacological targets in cancer therapy","volume":"24","author":"Sebastian","year":"2023","journal-title":"Curr. Drug Targets"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118112_bib5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/14728222.2024.2341630","article-title":"An update on the development on tubulin inhibitors for the treatment of solid tumors","volume":"28","author":"Yakkala","year":"2024","journal-title":"Expert Opin. Ther. Targets"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118112_bib6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1021\/ci8003336","article-title":"Identification and characterization of an intermediate taxol binding site within microtubule nanopores and a mechanism for tubulin isotype binding selectivity","volume":"49","author":"Freedman","year":"2009","journal-title":"J. Chem. Inf. Model."},{"issue":"24","key":"10.1016\/j.ejmech.2025.118112_bib7","doi-asserted-by":"crossref","first-page":"11598","DOI":"10.1073\/pnas.90.24.11598","article-title":"Localization of the colchicine-binding site of tubulin","volume":"90","author":"Uppuluri","year":"1993","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"25","key":"10.1016\/j.ejmech.2025.118112_bib8","doi-asserted-by":"crossref","first-page":"14707","DOI":"10.1074\/jbc.271.25.14707","article-title":"Localization of the vinblastine-binding site on \u03b2-tubulin","volume":"271","author":"Rai","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2025.118112_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0014-5793(77)80075-6","article-title":"Maytansine binding to the vinblastine sites of tubulin","volume":"75","author":"Bhattacharyya","year":"1977","journal-title":"FEBS Lett."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118112_bib10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chembiol.2004.03.028","article-title":"The anticancer natural product pironetin selectively targets Lys352 of \u03b1-tubulin","volume":"11","author":"Usui","year":"2004","journal-title":"Chem. Biol."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118112_bib11","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2021847118","article-title":"Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site","volume":"118","author":"Matthew","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"25","key":"10.1016\/j.ejmech.2025.118112_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/ange.202204052","article-title":"Rational design of a novel tubulin inhibitor with a unique mechanism of action","volume":"134","author":"M\u00fchlethaler","year":"2022","journal-title":"Angew. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118112_bib13","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2424098122","article-title":"Identification of a ligand-binding site on tubulin mediating the tubulin\u2013RB3 interaction","volume":"122","author":"Li","year":"2025","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118112_bib14","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/17460441.2022.2131766","article-title":"Strategies for the drug discovery and development of taxane anticancer therapeutics","volume":"17","author":"Wang","year":"2022","journal-title":"Expet Opin. Drug Discov."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118112_bib15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.chembiol.2008.05.008","article-title":"Optimization of taxane binding to microtubules: binding affinity dissection and incremental construction of a high-affinity analog of paclitaxel","volume":"15","author":"Matesanz","year":"2008","journal-title":"Chem. Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118112_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0163-7258(91)90081-V","article-title":"Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules","volume":"51","author":"Himes","year":"1991","journal-title":"Pharmacol. Therapeut."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118112_bib17","first-page":"82","article-title":"Resistance to anti-tubulin agents: from vinca alkaloids to epothilones","volume":"2","author":"Krause","year":"2019","journal-title":"Cancer Drug Resistance"},{"issue":"11","key":"10.1016\/j.ejmech.2025.118112_bib18","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.3390\/cancers12113323","article-title":"Mechanisms of taxane resistance","volume":"12","author":"Maloney","year":"2020","journal-title":"Cancers"},{"issue":"27","key":"10.1016\/j.ejmech.2025.118112_bib19","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.2174\/0929867327666200316144610","article-title":"Tubulin maytansine site binding ligands and their applications as MTAs and ADCs for cancer therapy","volume":"27","author":"Cao","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118112_bib20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.pharmthera.2015.12.006","article-title":"Microtubule-stabilizing agents: new drug discovery and cancer therapy","volume":"162","author":"Zhao","year":"2016","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2025.118112_bib21","doi-asserted-by":"crossref","first-page":"v3","DOI":"10.1093\/annonc\/mdm172","article-title":"Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents","volume":"18","author":"Fojo","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.118112_bib22","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ejmech.2017.11.062","article-title":"Recent advances in microtubule-stabilizing agents","volume":"143","author":"Cao","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118112_bib23","series-title":"Tubulin-Binding Agents: Synthetic, Structural and Mechanistic Insights","first-page":"279","article-title":"Molecular modeling approaches to study the binding mode on tubulin of microtubule destabilizing and stabilizing agents","author":"Botta","year":"2008"},{"key":"10.1016\/j.ejmech.2025.118112_bib24","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ejmech.2018.04.011","article-title":"Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site","volume":"151","author":"Li","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118112_bib25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/1871526517666171017114901","article-title":"Colchicine: a review on chemical structure and clinical usage","volume":"18","author":"Alkadi","year":"2018","journal-title":"Infectious Disorders-Drug TargetsDisorders)"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118112_bib26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.amjmed.2014.12.010","article-title":"Colchicine: old and new","volume":"128","author":"Slobodnick","year":"2015","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejmech.2025.118112_bib27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.vph.2016.05.006","article-title":"Vascular disrupting activity of combretastatin analogues","volume":"83","author":"Porc\u00f9","year":"2016","journal-title":"Vasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118112_bib28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/ph13010008","article-title":"Colchicine-binding site inhibitors from chemistry to clinic: a review","volume":"13","author":"McLoughlin","year":"2020","journal-title":"Pharmaceuticals"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118112_bib29","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1021\/jm801315b","article-title":"Discovery of N-(4-methoxyphenyl)-N, 2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration","volume":"52","author":"Sirisoma","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118112_bib30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11060-014-1437-y","article-title":"A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC)","volume":"118","author":"Chamberlain","year":"2014","journal-title":"Journal of neuro-oncology"},{"key":"10.1016\/j.ejmech.2025.118112_bib31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11060-012-0964-7","article-title":"Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme","volume":"110","author":"Grossmann","year":"2012","journal-title":"Journal of neuro-oncology"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118112_bib32","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1002\/alz.14083","article-title":"Exploring microtubule dynamics in Alzheimer's disease: longitudinal assessment using [11C] MPC\u20106827 PET imaging in rodent models of Alzheimer's\u2010related pathology","volume":"20","author":"Damuka","year":"2024","journal-title":"Alzheimer's Dement."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2025.118112_bib33","article-title":"Microtubule targeting agents in glioma","volume":"5","author":"Calinescu","year":"2016","journal-title":"Transl. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118112_bib34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cmdc.201100361","article-title":"The tubulin colchicine domain: a molecular modeling perspective","volume":"7","author":"Massarotti","year":"2012","journal-title":"ChemMedChem"},{"issue":"15","key":"10.1016\/j.ejmech.2025.118112_bib35","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.4155\/fmc-2017-0100","article-title":"Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures","volume":"9","author":"Li","year":"2017","journal-title":"Future Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118112_bib36","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1159\/000489983","article-title":"SKLB060 reversibly binds to colchicine site of tubulin and possesses efficacy in multidrug-resistant cell lines","volume":"47","author":"Yan","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118112_bib37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1752-153X-7-95","article-title":"Quinazoline derivatives: synthesis and bioactivities","volume":"7","author":"Wang","year":"2013","journal-title":"Chem. Cent. J."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118112_bib38","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1039\/C7MD00097A","article-title":"An insight into the therapeutic potential of quinazoline derivatives as anticancer agents","volume":"8","author":"Ahmad","year":"2017","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejmech.2025.118112_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116962","article-title":"Identification of furo [2, 3-d] pyrimidin-4-ylsulfanyl-1, 3, 4-thiadiazole derivatives as novel FLT3-ITD inhibitors","volume":"280","author":"Moradi","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118112_bib40","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2174\/1871520620666200627205321","article-title":"Bestowal of quinazoline scaffold in anticancer drug discovery","volume":"21","author":"Das","year":"2021","journal-title":"Anti-Cancer Agents in Medicinal Chemistry-Anti-Cancer Agents)"},{"issue":"15","key":"10.1016\/j.ejmech.2025.118112_bib41","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1021\/jm8003653","article-title":"Discovery of 2-chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (EP128265, MPI-0441138) as a potent inducer of apoptosis with high in vivo activity","volume":"51","author":"Sirisoma","year":"2008","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118112_bib42","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/j.bmcl.2010.01.155","article-title":"Discovery of N-methyl-4-(4-methoxyanilino) quinazolines as potent apoptosis inducers. Structure\u2013activity relationship of the quinazoline ring","volume":"20","author":"Sirisoma","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118112_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116376","article-title":"Design, synthesis and biological evaluation of novel acridine and quinoline derivatives as tubulin polymerization inhibitors with anticancer activities","volume":"46","author":"Ren","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118112_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115470","article-title":"Discovery of novel N-aryl-2-trifluoromethyl-quinazoline-4-amine derivatives as the inhibitors of tubulin polymerization in leukemia cells","volume":"256","author":"Wu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118112_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173093","article-title":"AQ-4, a deuterium-containing molecule, acts as a microtubule-targeting agent for cancer treatment","volume":"877","author":"Lin","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118112_bib46","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bioorg.2018.10.027","article-title":"Discovery of novel quinazolines as potential anti-tubulin agents occupying three zones of colchicine domain","volume":"83","author":"Li","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118112_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117000","article-title":"Discovery of novel quinazoline derivatives as tubulin polymerization inhibitors targeting the colchicine binding site with potential anti-colon cancer effects","volume":"280","author":"Zhu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118112_bib48","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/cbdd.12706","article-title":"Synthesis and biological evaluation of novel substituted 4\u2010Anilinoquinazolines as antitumor agents","volume":"96","author":"Cao","year":"2020","journal-title":"Chem. Biol. Drug Des."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118112_bib49","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.bmcl.2016.03.016","article-title":"Synthesis, in vitro and in vivo evaluation of novel substituted N-(4-(2-(4-benzylpiperazin-1-yl) ethoxy) phenyl)-N-methyl-quinazolin-4-amines as potent antitumor agents","volume":"26","author":"Cao","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118112_bib50","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ejmech.2017.07.040","article-title":"Design, synthesis and biological evaluation of 4-anilinoquinoline derivatives as novel potent tubulin depolymerization agents","volume":"138","author":"Zhou","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118112_bib51","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1021\/acs.jmedchem.8b00128","article-title":"Synthesis and biological evaluation of selenium-containing 4-anilinoquinazoline derivatives as novel antimitotic agents","volume":"61","author":"An","year":"2018","journal-title":"J. Med. Chem."},{"issue":"25","key":"10.1016\/j.ejmech.2025.118112_bib52","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1039\/C8OB00875B","article-title":"The design, synthesis and evaluation of selenium-containing 4-anilinoquinazoline hybrids as anticancer agents and a study of their mechanism","volume":"16","author":"An","year":"2018","journal-title":"Org. Biomol. Chem."},{"issue":"19","key":"10.1016\/j.ejmech.2025.118112_bib53","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1016\/j.bmcl.2012.08.014","article-title":"Design and synthesis of diarylamines and diarylethers as cytotoxic antitumor agents","volume":"22","author":"Wang","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118112_bib54","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.bmc.2012.11.047","article-title":"Synthesis and biological evaluation of N-alkyl-N-(4-methoxyphenyl) pyridin-2-amines as a new class of tubulin polymerization inhibitors","volume":"21","author":"Wang","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118112_bib55","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejmech.2013.06.041","article-title":"N-Aryl-6-methoxy-1, 2, 3, 4-tetrahydroquinolines: a novel class of antitumor agents targeting the colchicine site on tubulin","volume":"67","author":"Wang","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2025.118112_bib56","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1016\/j.bmc.2015.07.016","article-title":"Optimization of N-aryl-6-methoxy-1, 2, 3, 4-tetrahydroquinolines as tubulin polymerization inhibitors","volume":"23","author":"Wang","year":"2015","journal-title":"Bioorg. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2025.118112_bib57","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1021\/acs.jmedchem.7b00273","article-title":"In vivo and mechanistic studies on antitumor lead 7-methoxy-4-(2-methylquinazolin-4-yl)-3, 4-dihydroquinoxalin-2 (1 H)-one and its modification as a novel class of tubulin-binding tumor-vascular disrupting agents","volume":"60","author":"Cui","year":"2017","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118112_bib58","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1021\/acsmedchemlett.9b00352","article-title":"Scaffold hopping-driven optimization of 4-(quinazolin-4-yl)-3, 4-dihydroquinoxalin-2 (1 H)-ones as novel tubulin inhibitors","volume":"11","author":"Jiang","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118112_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117139","article-title":"Design, synthesis, and antitumor evaluation of quinazoline-4-tetrahydroquinoline chemotypes as novel tubulin polymerization inhibitors targeting the colchicine site","volume":"283","author":"Lai","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118112_bib60","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1021\/acs.jmedchem.7b01858","article-title":"Heterocyclic-fused pyrimidines as novel tubulin polymerization inhibitors targeting the colchicine binding site: structural basis and antitumor efficacy","volume":"61","author":"Banerjee","year":"2018","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2025.118112_bib61","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/cmdc.202000197","article-title":"Synthesis and anticancer properties of oxazepines related to azaisoerianin and IsoCoQuines","volume":"15","author":"Khelifi","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118112_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116061","article-title":"Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer","volume":"35","author":"Choudhary","year":"2021","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118112_bib63","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cmdc.201300531","article-title":"Effects of the tumor\u2010vasculature\u2010disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels","volume":"9","author":"Mahal","year":"2014","journal-title":"ChemMedChem"},{"issue":"17","key":"10.1016\/j.ejmech.2025.118112_bib64","doi-asserted-by":"crossref","first-page":"12964","DOI":"10.1021\/acs.jmedchem.1c01099","article-title":"Discovery of novel anti-breast-cancer inhibitors by synergistically antagonizing microtubule polymerization and aryl hydrocarbon receptor expression","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118112_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113656","article-title":"Anticancer properties of indole derivatives as IsoCombretastatin A-4 analogues","volume":"223","author":"Pecnard","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118112_bib66","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejmech.2019.02.038","article-title":"N, N-bis-heteroaryl methylamines: potent anti-mitotic and highly cytotoxic agents","volume":"168","author":"Khelifi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118112_bib67","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1021\/ml5004684","article-title":"Synthesis and structure\u2013activity relationship study of 1-phenyl-1-(quinazolin-4-yl) ethanols as anticancer agents","volume":"6","author":"Kuroiwa","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118112_bib68","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.dyepig.2017.05.050","article-title":"Fluorescent anticancer quinazolines as molecular probes for \u03b2-tubulin colchicine site competition assay and visualization of microtubules as intracellular targeting sites","volume":"145","author":"Suzuki","year":"2017","journal-title":"Dyes Pigments"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118112_bib69","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1021\/acsmedchemlett.0c00119","article-title":"Discovery of a potent anticancer agent PVHD303 with in vivo activity","volume":"11","author":"Suzuki","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118112_bib70","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/cmdc.201500069","article-title":"IsoCombretaQuinazolines: potent cytotoxic agents with antitubulin activity","volume":"10","author":"Soussi","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118112_bib71","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ejmech.2016.11.012","article-title":"Design, synthesis and anticancer properties of IsoCombretaQuinolines as potent tubulin assembly inhibitors","volume":"127","author":"Khelifi","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118112_bib72","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1021\/acs.jmedchem.8b01386","article-title":"1, 1-Diheterocyclic ethylenes derived from quinaldine and carbazole as new tubulin-polymerization inhibitors: synthesis, metabolism, and biological evaluation","volume":"62","author":"Naret","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118112_bib73","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejmech.2018.11.070","article-title":"Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site","volume":"163","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2025.118112_bib74","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1016\/j.bmcl.2009.04.145","article-title":"Discovery of 4-anilino-N-methylthieno [3, 2-d] pyrimidines and 4-anilino-N-methylthieno [2, 3-d] pyrimidines as potent apoptosis inducers","volume":"19","author":"Kemnitzer","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118112_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116791","article-title":"Discovery of novel thiophene [3, 2-d] pyrimidine-based tubulin inhibitors with enhanced antitumor efficacy for combined use with anti-pd-l1 immunotherapy in melanoma","volume":"277","author":"Xu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118112_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116649","article-title":"Discovery and mechanistic insights into thieno [3, 2-d] pyrimidine and heterocyclic fused pyrimidines inhibitors targeting tubulin for cancer therapy","volume":"276","author":"Wu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118112_bib77","article-title":"Discovery of novel thienopyridine indole derivatives as inhibitors of tubulin polymerization targeting the colchicine-binding site with potent anticancer activities","author":"Liu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2025.118112_bib78","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1016\/j.bmc.2014.04.049","article-title":"The design and discovery of water soluble 4-substituted-2, 6-dimethylfuro [2, 3-d] pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents","volume":"22","author":"Zhang","year":"2014","journal-title":"Bioorg. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118112_bib79","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/j.bmc.2015.03.061","article-title":"The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2, 6-dimethylfuro [2, 3-d] pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents","volume":"23","author":"Zhang","year":"2015","journal-title":"Bioorg. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118112_bib80","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1021\/acs.jmedchem.6b00237","article-title":"Design, synthesis, and preclinical evaluation of 4-substituted-5-methyl-furo [2, 3-d] pyrimidines as microtubule targeting agents that are effective against multidrug resistant cancer cells","volume":"59","author":"Devambatla","year":"2016","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2025.118112_bib81","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1016\/j.bmcl.2018.07.039","article-title":"Design, synthesis and preclinical evaluation of 5-methyl-N4-aryl-furo [2, 3-d] pyrimidines as single agents with combination chemotherapy potential","volume":"28","author":"Devambatla","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"22","key":"10.1016\/j.ejmech.2025.118112_bib82","doi-asserted-by":"crossref","first-page":"8116","DOI":"10.1021\/jm101010n","article-title":"Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance","volume":"53","author":"Gangjee","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118112_bib83","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1007\/s11095-012-0816-3","article-title":"Novel water-soluble substituted pyrrolo [3, 2-d] pyrimidines: design, synthesis, and biological evaluation as antitubulin antitumor agents","volume":"29","author":"Gangjee","year":"2012","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118112_bib84","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1021\/ml4004793","article-title":"Discovery of antitubulin agents with antiangiogenic activity as single entities with multitarget chemotherapy potential","volume":"5","author":"Gangjee","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118112_bib85","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.bmc.2016.11.026","article-title":"Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo [3, 2-d] pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents","volume":"25","author":"Pavana","year":"2017","journal-title":"Bioorg. Med. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2025.118112_bib86","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1016\/j.bmc.2018.09.025","article-title":"Sterically induced conformational restriction: discovery and preclinical evaluation of novel pyrrolo [3, 2-d] pyrimidines as microtubule targeting agents","volume":"26","author":"Pavana","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118112_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127923","article-title":"Novel pyrazolo [4, 3-d] pyrimidine microtubule targeting agents (MTAs): Synthesis, structure\u2013activity relationship, in vitro and in vivo evaluation as antitumor agents","volume":"41","author":"Islam","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118112_bib88","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejmech.2014.09.093","article-title":"Synthesis and antiproliferative activity of 6-phenylaminopurines","volume":"87","author":"Canela","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118112_bib89","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1021\/acs.jmedchem.2c02115","article-title":"Design, synthesis, and biological evaluation of heterocyclic-fused pyrimidine chemotypes guided by X-ray crystal structure with potential antitumor and anti-multidrug resistance efficacy targeting the colchicine binding site","volume":"66","author":"Tan","year":"2023","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118112_bib90","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1021\/acschembio.9b00696","article-title":"X-ray crystal structure guided discovery and antitumor efficacy of dihydroquinoxalinone as potent tubulin polymerization inhibitors","volume":"14","author":"Arnst","year":"2019","journal-title":"ACS Chem. Biol."},{"issue":"17","key":"10.1016\/j.ejmech.2025.118112_bib91","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1021\/jm2007722","article-title":"Synthesis and biological activities of (R)-and (S)-N-(4-methoxyphenyl)-N, 2, 6-trimethyl-6, 7-dihydro-5 H-cyclopenta [d] pyrimidin-4-aminium chloride as potent cytotoxic antitubulin agents","volume":"54","author":"Gangjee","year":"2011","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2025.118112_bib92","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.1021\/jm400639z","article-title":"Structure\u2013activity relationship and in vitro and in vivo evaluation of the potent cytotoxic anti-microtubule agent N-(4-Methoxyphenyl)-N, 2, 6-trimethyl-6, 7-dihydro-5 H-cyclopenta [d] pyrimidin-4-aminium chloride and its analogues as antitumor agents","volume":"56","author":"Gangjee","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118112_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115887","article-title":"The 3-D conformational shape of N-naphthyl-cyclopenta [d] pyrimidines affects their potency as microtubule targeting agents and their antitumor activity","volume":"29","author":"Xiang","year":"2021","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118112_bib94","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1021\/acsptsci.2c00108","article-title":"Design, synthesis, and biological evaluation of pyrimidine dihydroquinoxalinone derivatives as tubulin colchicine site-binding agents that displayed potent anticancer activity both in vitro and in vivo","volume":"6","author":"Pochampally","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118112_bib95","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3390\/ph16101499","article-title":"Verubulin (Azixa) analogues with increased saturation: Synthesis, SAR and encapsulation in biocompatible nanocontainers based on Ca2+ or Mg2+ cross-linked alginate","volume":"16","author":"Sedenkova","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118112_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114467","article-title":"Discovery of novel coumarin-indole derivatives as tubulin polymerization inhibitors with potent anti-gastric cancer activities","volume":"238","author":"Song","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118112_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106580","article-title":"Discovery of a novel coumarin-dihydroquinoxalone derivative MY-673 as a tubulin polymerization inhibitor capable of inhibiting the ERK pathway with potent anti-gastric cancer activities","volume":"137","author":"Song","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118112_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116079","article-title":"Discovery of novel coumarin-based derivatives as inhibitors of tubulin polymerization targeting the colchicine binding site with potent anti-gastric cancer activities","volume":"265","author":"Tian","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118112_bib99","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.bmc.2012.12.010","article-title":"Synthesis of N4-(substituted phenyl)-N4-alkyl\/desalkyl-9H-pyrimido [4, 5-b] indole-2, 4-diamines and identification of new microtubule disrupting compounds that are effective against multidrug resistant cells","volume":"21","author":"Gangjee","year":"2013","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118112_bib100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/molecules27010321","article-title":"Design, synthesis, and biological evaluation of 5, 6, 7, 8-Tetrahydrobenzo [4, 5] thieno [2, 3-d] pyrimidines as microtubule targeting agents","volume":"27","author":"Islam","year":"2022","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.ejmech.2025.118112_bib101","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1021\/acs.jmedchem.5b01342","article-title":"Discovery of selective histone deacetylase 6 inhibitors using the quinazoline as the cap for the treatment of cancer","volume":"59","author":"Yang","year":"2016","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2025.118112_bib102","doi-asserted-by":"crossref","first-page":"15379","DOI":"10.1021\/acs.jmedchem.1c01451","article-title":"Discovery of a series of hydroxamic acid-based microtubule destabilizing agents with potent antitumor activity","volume":"64","author":"Yang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118112_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114573","article-title":"Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors","volume":"240","author":"Hauguel","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118112_bib104","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/cbdd.13405","article-title":"Design, synthesis, and biological evaluation of quinazoline derivatives as dual HDAC 1 and HDAC 6 inhibitors for the treatment of cancer","volume":"93","author":"Chen","year":"2019","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2025.118112_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115529","article-title":"Synthesis and bioevaluation of novel stilbene-based derivatives as tubulin\/HDAC dual-target inhibitors with potent antitumor activities in vitro and in vivo","volume":"257","author":"Zhu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118112_bib106","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118112_bib107","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/cells9051083","article-title":"Tubulin resists degradation by cereblon-recruiting PROTACs","volume":"9","author":"Gasic","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.118112_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116067","article-title":"Discovery of the cereblon-recruiting tubulin PROTACs effective in overcoming taxol resistance in vitro and in vivo","volume":"265","author":"Yang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2025.118112_bib109","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1158\/0008-5472.CAN-18-0989","article-title":"The NCI transcriptional pharmacodynamics workbench: a tool to examine dynamic expression profiling of therapeutic response in the NCI-60 cell line panel","volume":"78","author":"Monks","year":"2018","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118112_bib110","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1186\/s12885-022-09580-7","article-title":"Pharmacogenomics of in vitro response of the NCI-60 cancer cell line panel to Indian natural products","volume":"22","author":"Sankaran","year":"2022","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118112_bib111","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1054\/bjoc.2001.1956","article-title":"Modulation of endogenous \u03b2-tubulin isotype expression as a result of human \u03b2IIIcDNA transfection into prostate carcinoma cells","volume":"85","author":"Ranganathan","year":"2001","journal-title":"Br. J. Cancer"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T21:31:47Z","timestamp":1772832707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425008773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":111,"alternative-id":["S0223523425008773"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118112","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Verubulin and its derivatives: Progress and promise in tubulin-targeted cancer therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118112"}}